AMINO ACIDS - Generic Drug Details

What are the generic sources for amino acids and what is the scope of freedom to operate?

Amino acids is the generic ingredient in one hundred and thirty-nine branded drugs marketed by Hospira, B Braun, Icu Medical Inc, Abbott, Otsuka Icu Medcl, Baxter Hlthcare, Hospira Inc, and Fresenius Kabi Usa, and is included in fifty-five NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for amino acids. Four suppliers are listed for this compound.

Summary for AMINO ACIDS

US Patents:	1
Tradenames:	139
Applicants:	8
NDAs:	55
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	4
DailyMed Link:	AMINO ACIDS at DailyMed

Pharmacology for AMINO ACIDS

Drug Class

Amino Acid

Anatomical Therapeutic Chemical (ATC) Classes for AMINO ACIDS

B05BA	Solutions for parenteral nutrition
B05B	I.V. SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

US Patents and Regulatory Information for AMINO ACIDS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	PREMASOL 6% IN PLASTIC CONTAINER	amino acids	INJECTABLE;INJECTION	075880-001	Jun 19, 2003		RX	No	No
Icu Medical Inc	AMINOSYN 3.5% M	amino acids; magnesium acetate; potassium acetate; sodium chloride	INJECTABLE;INJECTION	017789-005	Approved Prior to Jan 1, 1982		DISCN	No	No
Icu Medical Inc	AMINOSYN II 8.5%	amino acids	INJECTABLE;INJECTION	019438-004	Apr 3, 1986		DISCN	No	No
Abbott	AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019713-003	Sep 9, 1988		DISCN	No	No
Hospira Inc	AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER	amino acids; calcium chloride; dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride	INJECTABLE;INJECTION	019683-001	Nov 7, 1988		DISCN	No	No
Abbott	AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019504-002	Nov 7, 1986		DISCN	No	No

Expired US Patents for AMINO ACIDS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	BRANCHAMIN 4%	amino acids	INJECTABLE;INJECTION	018678-001	Sep 28, 1984	4,438,144
Baxter Hlthcare	BRANCHAMIN 4% IN PLASTIC CONTAINER	amino acids	INJECTABLE;INJECTION	018684-001	Sep 28, 1984	4,438,144
B Braun	HEPATAMINE 8%	amino acids	INJECTABLE;INJECTION	018676-001	Aug 3, 1982	3,950,529

AMINO ACIDS Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Overview of Amino Acids in Pharmaceuticals

The amino acids segment within pharmaceuticals is characterized by stable demand driven by multiple applications, including nutritional supplementation, biopharmaceuticals, and diagnostic tools. The global amino acids market was valued at approximately $4.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 7% from 2023 to 2030. This growth trajectory aligns with increasing healthcare awareness, rising adoption of amino acid-based therapeutics, and advances in biotechnological manufacturing processes.

Market Drivers and Constraints

Demand Drivers:

• Nutritional Supplements: Growing consumer awareness related to health and wellness fuels dietary amino acid supplements. These products are used to improve muscle recovery, cognitive function, and immune health.

• Biopharmaceutical Development: Amino acids are essential components in cell culture media for monoclonal antibody (mAb) and recombinant protein production, promoting their use in bioprocessing. The expansion of biologics therapies significantly boosts demand.

• Diagnostic Applications: Research and diagnostic tools utilizing amino acids for metabolic profiling and disease markers drive steady growth.

• Aging Population: Increased prevalence of age-related diseases prompts higher use of amino acid-based therapies.

Market Constraints:

• Price Volatility: Prices for raw materials like corn, sugarbeet, and cassava, used in fermentation-based amino acid manufacturing, are susceptible to agricultural market fluctuations.

• Regulatory Hurdles: Stringent approvals for amino acid supplements and pharmaceutical ingredients restrict rapid market entry and may increase compliance costs.

• Alternative Technologies: Advances in synthetic biology or novel biomolecules could replace traditional amino acids in some applications, impacting growth.

Market Segmentation and Key Players

Segment by Type:

Amino Acid	Market Share (2022)	Key Applications
L-Glutamine	20%	Sports nutrition, cell culture media
L-Lysine	18%	Nutritional supplements, animal feed
L-Arginine	15%	Cardiovascular health, immune support
Others	47%	Pharmaceuticals, diagnostics, research

Leading Companies:

• Ajinomoto Co., Inc.
• Evonik Industries -CJ CheilJedang
• Maitland Biotechnology
• Showa Kako Co.

These companies hold significant manufacturing capacity and R&D investments, boosting product innovation and diversification.

Financial Trajectory

Historical Revenue (2022): Approximate revenues of major players indicate the following:

• Ajinomoto: $2.3 billion (pharmaceutical and amino acid segments)
• Evonik: $1 billion from amino acids and derivatives
• CJ CheilJedang: $400 million, primarily for lysine and glutamine

Future Projections (2023–2030):

Year	Estimated Market Size	Compound Annual Growth Rate (CAGR)	Notes
2023	$4.56 billion	—	Base year
2025	$5.3 billion	7%	Growth driven by biopharma
2030	$7.2 billion	—	Increased demand in biologics

Revenue Streams Breakdown:

• Nutraceuticals and Food Additives: Approximately 45%
• Pharmaceutical and Biopharma Manufacturing: 40%
• Diagnostics and Research: 15%

Strategic Trends

• Vertical Integration: Major firms invest in raw material cultivation or fermentation capabilities to control supply and costs.

• Product Diversification: Focus on specialty amino acids and derivatives, addressing specific therapeutic niches.

• Sustainability: Brands adopting eco-friendly manufacturing practices and renewable raw materials to appeal to regulatory and consumer preferences.

• Technological Innovation: Emerging bioengineering techniques enable higher yield microbial fermentation with reduced costs.

Regulatory Environment and Impact

International agencies, including the FDA and EMA, enforce strict standards for amino acid formulations used in pharmaceuticals. New approvals or safety concerns can significantly influence market dynamics. In 2021, the US FDA issued guidance emphasizing product purity and traceability, impacting manufacturing practices and costs.

Competitive and Investment Outlook

Market competition remains intense, driven by capacity expansions and R&D toward novel derivatives. Investment in bioprocessing innovation is a primary focus, especially in jurisdictions with robust biotech ecosystems like North America, Europe, and parts of Asia.

Key Takeaways

• The amino acids market in pharma is growing steadily, with a CAGR of 7% expected through 2030.
• Demand is primarily fueled by biologics manufacturing and nutritional health.
• Raw material costs and regulatory requirements represent primary constraints.
• Major firms focus on capacity expansion, product diversification, and sustainability.
• The market remains highly competitive, with innovation centered around fermentation technology and specialty amino acids.

FAQs

What are the primary drivers of amino acids market growth?
Nutritional supplement demand, biopharmaceutical applications, aging population health needs, and diagnostic research.

Which amino acids lead the market?
L-Glutamine, L-Lysine, and L-Arginine are dominant, collectively accounting for around 53% of the market share.

How do raw material prices influence the market?
Fluctuations can impact manufacturing costs and product pricing, affecting profit margins and supply stability.

What regulatory challenges exist?
Compliance with FDA, EMA, and other agency standards regarding safety, purity, and manufacturing processes shapes market strategy.

What is the outlook for future R&D investments?
Investments are increasing in bioprocessing innovations, sustainable practices, and specialty amino acid derivatives to capitalize on emerging applications.

---

Sources:

1. MarketsandMarkets. "Amino Acids Market by Type, Application, and Region," 2022.
2. Research and Markets. "Global Amino Acids Market Analysis," 2023.
3. Ajinomoto Co., Inc. Annual Report 2022.
4. Evonik Industries. Financial Statements 2022.
5. FDA Guidelines for Amino Acid Products, 2021.